transcriptomics

RNA sequencing of patient-derived fibroblasts was able to provide 10 percent of patients with a diagnosis after whole-exome sequencing had failed.

The company plans to use the proceeds to support research collaborations and to expand its commercial team.

ReadCoor is currently using its its technology to map neural circuits in the brain and has projects in the pipeline related to oncology and infectious disease.